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Although chronic lung disease is the most serious clinical expression of CF, and
the majority of patients die from respiratory failure, a relationship between CFTR
genotype and severity of pulmonary disease in CF has proven difﬁcult to establish.
Therefore, we investigated the relationship between CFTR genotype models based
on molecular genetic criteria ( (i) class I−V, (ii) nature of mutations, (iii) gene
regions, (iv) protein regions, (v) nature and localisation of mutations, (vi) speciﬁc
genotypes) and the progression of lung disease based on lung function parameters
(FRCpleth, LCI, VTG, sReff , FEV1, FEF50) in a well characterised cohort of 204
CF patients followed during a life span from 6 to 20 years. Linear mixed model
(LMM) analyses were used to analyse the relationship between each lung function
parameter and age in the genetic groups i−vi, the slope representing progression.
We found that, depending on the nature and/or localisation of the mutations,
discrimination between genetic subgroups resulted from different functional lung
characteristics. Moreover, if genotypes are stratiﬁed according to the presence
or absence of F508del and subgrouped according to the nature of mutations,
discrimination can be achieved by all lung function parameters demonstrating
best association with FRCpleth and FEF50. The data demonstrate that extended
lung function evaluation is needed to provide evidence for genotype-phenotype
associations in CF, and that genotype modelling may be a helpful prognostic tool
even though it is beyond doubt that many other modifying factors contribute to the
CF phenotype.
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The ACE gene encodes angiotensin-converting enzyme is an enzyme related to pro-
inﬂammatory response. This gene presents a polymorphism called D/I, the D allele
is characterized by the deletion of 287pb in intron 16 and responsible for higher
expression of the gene.
Objective: To link the polymorphism D/I in ACE gene with the clinical markers of
CF (Shwachman score, body mass index-BMI, age at diagnosis, early pulmonary
and gastrointestinal symptoms, microorganisms present, spirometry, oxygen satura-
tion).
Method: 181CF patients, 95 (52.6%) males, mean age 15 years. For the analysis
of polymorphism D/I was used the technique of PCR. Statistical analysis was
performed by SPSS v.10.0. The analysis of quantitative data was performed by
analysis of variance for a factor and qualitative data by logistic regression test and
Odds Ratio (OR).
Results and Discussion: For patients with allele D, the diagnosis was made on
average before the three years of age when compared to individuals homozygous II
(OR: 3.07, CI = 1.1−2.6). As for the appearance of the table digestive same occurred
(OR: 8.2, CI = 1.4−1.5). As for the Shwachman score, was observed a greater
number of patients with genotype DD with scores classiﬁed as severe (OR: 6.4, CI =
1.2–34.2). These results suggest that increased expression of ACE resulting of DD
genotype leads to greater lung damage due to inﬂammation. But the genotype DD
seems to protect against chronic infection that can be observed by the presence of
greater numbers of patients with genotype II infected by the bacteria Achromobacter
xylosoxidans (OR: 4.5, CI = 1.2–17.1; RR: 3.5, CI = 1.3−9.7).
Conclusion: The polymorphism D/I in the ACE gene acts as modiﬁer in CF.
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For the present study were chosen candidate genes related to modifying the
mechanism of action of glutathione (GSH).
Objective: To link the presence of polymorphisms (pol.) of GST and GCLC genes
with the degree of seriousness.
Method: 181 patients, 52.6% males, mean age: 15 years. We used the technique
of PCR in the genes GSTM1 and T1 for the GSTP1 (pol.313A/G) and GCLC
(pol.129C/T and 350A/G) genes was also used restriction enzyme. The data were
correlated with: Kanga (EK) and Shwachman (ES) score, BMI, age at diagnosis,
onset of symptoms, isolated microorganisms, spirometry and SaO2. Statistical
analysis was performed by analysis of variance for a factor, logistic regression
test and Odds Ratio (OR).
Results: For the GSTM1, GCLC (pol.129C/T) and GSTP1 gene weren‘t statistically
signiﬁcant correlation with clinical markers. For the GSTT1 gene, individuals with
at least one allele coding, were classiﬁed in the category of low BMI (OR:3.1,
CI=1.4−7.1), when GSTM1 and T1 genes were analyzed simultaneously, the same
occurred (OR:1.5, CI=1.1−2.7). Patients with M1 and T1 genes with null alleles had
the lowest SaO2 (OR:4.3, CI=1.2–20.1) and worst ranking for ES (OR:9.0, CI=1.5–
55.1). Regarding the association of bacterial colonization to null allele for T1 and
coding to M1 was related to the presence of Pseudomonas aeruginosa mucoid
(OR:3.1, CI=1.3−7.6) and non mucoid (OR:4.8, CI=1.7–13.7). For GCLC350(A/G)
pol. of the GCLC gene was found a association to genotype A/A with SaO2
(OR:5.8, CI=2.3–14.5) and with worse rating for EK, lower value of FEF25−75%
and FEV1/FVC, and more severe regarding FEV1 (OR:4.6, CI=1.3−5.2).
Conclusion: GSTM1, GSTT1 and GCLC (pol.350A/G) genes act as modiﬁers in
CF.
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Objective/hypothesis: The aim of this study was to address whether nasal polyposis
(NP) might be a factor associated with a lower severity of cystic ﬁbrosis (CF).
Study design: We collected data of literature on NP as a unique or associated sign
in CF and reviewed the clinical and molecular aspects of CF associated with NP.
Methods:
1. We carried out a comprehensive analysis of literature on CF patients with and
without NP, using the Pubmed site. We reviewed CF genotypes and clinical
severity in NP(+) vs. NP(−) patients, lung function, P. aeruginosa infection,
nutritional and pancreatic status.
2. Furthermore, we analyzed the CFTR gene in a 26 years old patient with isolated
severe NP as the single feature of CF.
Results:
1. This literature study showed a “milder” phenotype in “NP+” vs. “NP−” CF pa-
tients, contrasting with a marked association between NP and “severe” CF
mutations.
2. In addition, we identiﬁed a complex genotype, four heterozygous variants,
namely p.Q493X (a severe mutation) on the paternal allele, p.V562I, p.A1006E,
(TG)11(T)5 (IVS8−5T) on the maternal allele, in a CF case presenting as isolated
NP.
Conclusions: We speculate that genetic/environmental factors associated with NP
might attenuate the functional impact of “severe” CF mutations. Furthermore, over
representation of CF carriers among patients with isolated NP, advocates CFTR
molecular screening in such a population for genetic counselling purpose.
Supported by “Mucoviscidose ABCF”.
